6748.TWO ACRO Biomedical Co., Ltd.
- Market cap
- TWD 11.5B
- P/E
- -
- P/B
- 11.97x
- ROE
- -7.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6748.TWO undervalued?
Graham numberThe Graham number of ACRO Biomedical Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ACRO Biomedical Co., Ltd. fundamental analysis
No fundamental analysis for ACRO Biomedical Co., Ltd. yet.
ACRO Biomedical Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ACRO Biomedical Co., Ltd.
ACRO Biomedical Co., Ltd. develops medical-grade regenerative biomaterials in Taiwan, Vietnam, and internationally. The company engages in manufacturing medical devices and cosmetics; research, design, production, and sales of biological tissue implants; and dental and orthopedic implants, collagen, and related derivative products. It also offers products in the areas of wound care, orthopedics, dentistry, ophthalmology, cosmetic micro plastic surgery, beauty and eye care, a…
Full company profileACRO Biomedical Co., Ltd. financial statements
ACRO Biomedical Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 18.0M | 21.8M | 27.6M | 51.1M | 44.2M | 38.3M |
| Gross Profit | - | 8.58M | 14.5M | 13.4M | 39.1M | 26.2M | 18.5M |
| Operating Income | - | -56.0M | -53.6M | -62.8M | -48.7M | -66.5M | -92.9M |
| EBITDA | -45.2M | -37.4M | -41.2M | -51.6M | -30.2M | -48.3M | -65.9M |
| Net Income | - | -50.0M | -50.8M | -60.9M | -41.4M | -62.1M | -82.7M |
| EPS | - | -1.65 | -1.43 | -1.29 | -0.79 | -1.01 | -1.16 |
| Balance Sheet | |||||||
| Total Assets | 148M | 203M | 151M | 399M | 717M | 655M | 1.13B |
| Total Liabilities | 23.0M | 25.0M | 21.3M | 19.9M | 30.7M | 29.1M | 28.1M |
| Shareholders' Equity | 125M | 178M | 130M | 379M | 686M | 626M | 1.10B |
| Cash & Short-term Investments | 55.5M | 117M | 63.0M | 317M | 579M | 499M | 771M |
| Total Debt | 16.0M | 16.8M | 13.4M | 11.8M | 21.7M | 15.8M | - |
| Cash Flow | |||||||
| Operating Cash Flow | - | -31.3M | -47.8M | -45.2M | -48.3M | -43.4M | -49.0M |
| Capital Expenditure | - | 3.83M | 3.30M | 4.44M | 22.5M | 30.6M | 14.0M |
| Free Cash Flow | - | -35.2M | -51.1M | -49.6M | -70.7M | -74.0M | -63.0M |
| Ratios | |||||||
| ROE | - | -28.0% | -39.1% | -16.1% | -6.0% | -9.9% | -7.5% |
| ROA | - | -24.6% | -33.6% | -15.3% | -5.8% | -9.5% | -7.3% |
| Net Profit Margin | - | -277.4% | -232.6% | -220.3% | -81.1% | -140.4% | -216.1% |
| Debt to Equity | 0.13x | 0.09x | 0.10x | 0.03x | 0.03x | 0.03x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ACRO Biomedical Co., Ltd. dividends
ACRO Biomedical Co., Ltd. has not paid dividends in the last 6 fiscal years.
Who owns ACRO Biomedical Co., Ltd.
Ownership data of ACRO Biomedical Co., Ltd. is not available yet.
ACRO Biomedical Co., Ltd. company profile
- Company name
- ACRO Biomedical Co., Ltd.
- Ticker
- 6748.TWO
- ISIN
- TW0006748007
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No.57, Luke 2nd Road, Kaohsiung, Taiwan, 82151
- Phone
- 886 7 695 5569
- Website
- acrobiomedical.com
About ACRO Biomedical Co., Ltd.
ACRO Biomedical Co., Ltd. develops medical-grade regenerative biomaterials in Taiwan, Vietnam, and internationally. The company engages in manufacturing medical devices and cosmetics; research, design, production, and sales of biological tissue implants; and dental and orthopedic implants, collagen, and related derivative products. It also offers products in the areas of wound care, orthopedics, dentistry, ophthalmology, cosmetic micro plastic surgery, beauty and eye care, and tissue engineering and regenerative medicines. ACRO Biomedical Co., Ltd. was founded in 2014 and is based in Kaohsiung, Taiwan.
ACRO Biomedical Co., Ltd. management
2- Dr. Dar-Jen HsiehChairman & CEO
- Min He WangAccounting Supervisor